Depressive symptoms and non-adherence to treatable cardiovascular risk factors' medications in the CONSTANCES cohort. Issue 4 (28th October 2020)

• Record Type: Journal Article
• Authors: Hamieh, Nadine; Kab, Sofiane; Zins, Marie; Blacher, Jacques; Meneton, Pierre; Empana, Jean-Philippe; Hoertel, Nicolas; Limosin, Frederic; Goldberg, Marcel; Melchior, Maria; Lemogne, Cedric
• Is Part Of: European heart journal. Volume 7:Issue 4(2021)
• Page Start: 280
• Page End: 286
• Publication Date: 2020-10-28
• Subjects: Depressive symptoms -- Hypertension -- Diabetes -- Dyslipidaemia -- Medication -- Adherence; Cardiovascular pharmacology -- Periodicals; 615.71
• DOI: 10.1093/ehjcvp/pvaa124
• Languages: English
• ISSNs: 2055-6837

Abstract

Abstract: Aims: Depression is associated with increased risk of cardiovascular disease (CVD) and the role of poor medical adherence is mostly unknown. We studied the association between depressive symptoms and non-adherence to medications targeting treatable cardiovascular risk factors in the CONSTANCES population-based French cohort. Methods and results: We used CONSTANCES data linked to the French national healthcare database to study the prospective association between depressive symptoms (assessed at inclusion with the Center for Epidemiological Studies Depression scale) and non-adherence to medications (less than 80% of trimesters with at least one drug dispensed) treating type 2 diabetes, hypertension, and dyslipidaemia over 36 months of follow-up. Binary logistic regression models were adjusted for socio-demographics, body mass index, and personal history of CVD at inclusion. Among 4998 individuals with hypertension, 793 with diabetes, and 3692 with dyslipidaemia at baseline, respectively 13.1% vs. 11.5%, 10.5% vs. 5.8%, and 29.0% vs. 27.1% of those depressed vs. those non-depressed were non-adherent over the first 18 months of follow-up (15.9% vs. 13.6%, 11.1% vs. 7.4%, and 34.8% vs. 36.6% between 19 and 36 months). Adjusting for all covariates, depressive symptoms were neither associated with non-adherence to medications for hypertension, diabetes, and dyslipidaemia over the first 18 months of follow-up, nor afterwards. Depressive symptoms were only associated with non-adherence to anti-diabetic medications between the first 3–6 months of follow-up. Conclusion: Non-adherence to medications targeting treatable cardiovascular risk factors is unlikely to explain much of the association between depressive symptoms and CVD at a population level. Clinicians are urged to search for and treat depression in individuals with diabetes to foster medications adherence.